{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:18:29Z","timestamp":1792603109440,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"am","delay-in-days":390,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anaesthesia Critical Care & Pain Medicine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.accpm.2019.07.016","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T19:11:50Z","timestamp":1568056310000},"page":"87-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetic variability of beta-lactams in critically ill patients: A narrative review"],"prefix":"10.1016","volume":"39","author":[{"given":"Cl\u00e9ment","family":"Boidin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastou","family":"Moshiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dahyot-Fizelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Lefeuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.accpm.2019.07.016_bib0605","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","article-title":"Sepsis in European intensive care units: results of the SOAP study","volume":"34","author":"Vincent","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.accpm.2019.07.016_bib0610","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/cc8945","article-title":"Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.07.016_bib0615","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/cc9091","article-title":"Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.07.016_bib0620","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.accpm.2019.07.016_bib0625","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.accpm.2019.07.016_bib0630","doi-asserted-by":"crossref","first-page":"R206","DOI":"10.1186\/cc10441","article-title":"Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of \u03b2-lactams","volume":"15","author":"Gon\u00e7alves-Pereira","year":"2011","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.accpm.2019.07.016_bib0635","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-016-0145-5","article-title":"Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies)","volume":"2","author":"Ichai","year":"2012","journal-title":"Ann Intens Care"},{"key":"10.1016\/j.accpm.2019.07.016_bib0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11318140-000000000-00000","article-title":"Augmented renal clearance: implications for antibacterial dosing in the critically ill","volume":"49","author":"Udy","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.accpm.2019.07.016_bib0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2015.06.002","article-title":"Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization","volume":"24","author":"Sime","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.accpm.2019.07.016_bib0650","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/0091270004269796","article-title":"Influence of renal function on the Pharmacokinetics of Piperacillin\/Tazobactam in intensive care unit patients during continuous venovenous hemofiltration","volume":"45","author":"Arzuaga","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.accpm.2019.07.016_bib0655","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/CCM.0b013e318241e553","article-title":"Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study","volume":"40","author":"Roberts","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.accpm.2019.07.016_bib0660","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.accpm.2019.07.016_bib0665","doi-asserted-by":"crossref","DOI":"10.1186\/2110-5820-2-35","article-title":"Does beta-lactam pharmacokinetic variability in critically III patients justify therapeutic drug monitoring? A systematic review","author":"Sime","year":"2012","journal-title":"Ann Intens Care"},{"key":"10.1016\/j.accpm.2019.07.016_bib0670","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"10.1016\/j.accpm.2019.07.016_bib0675","series-title":"The pharmacological basis of therapeutics 12th edition","author":"Goodman Gilman's","year":"2011"},{"key":"10.1016\/j.accpm.2019.07.016_bib0680","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1128\/AAC.17.2.199","article-title":"Absorption and disposition kinetics of amoxicillin in normal human subjects","volume":"17","author":"Arancibia","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0685","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2125.1975.tb01566.x","article-title":"Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis","volume":"2","author":"Nauta","year":"1975","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.accpm.2019.07.016_bib0690","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01477-06","article-title":"Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers","volume":"51","author":"Bulitta","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0695","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/jac\/10.4.295","article-title":"Temocillin, in-vitro activity and the pharmacokinetics and tissue penetration in healthy volunteers","volume":"10","author":"Brown","year":"1982","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0700","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1128\/AAC.23.6.831","article-title":"Pharmacokinetics and tissue penetration of ticarcillin combined with clavulanic acid","volume":"23","author":"Bennett","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl","key":"10.1016\/j.accpm.2019.07.016_bib0705","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1093\/infdis\/128.Supplement_2.S341","article-title":"Pharmacokinetics of cefazolin compared with four other cephalosporins","volume":"128","author":"Kirby","year":"1973","journal-title":"J Infect Dis"},{"key":"10.1016\/j.accpm.2019.07.016_bib0710","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.36.3.552","article-title":"Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects","volume":"36","author":"Barbhaiya","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0715","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/j.1552-4604.1992.tb03834.x","article-title":"Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers","volume":"32","author":"Nakayama","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.accpm.2019.07.016_bib0720","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1128\/AAC.34.12.2307","article-title":"Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers","volume":"34","author":"Mouton","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0725","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/jac\/dkg003","article-title":"Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers","volume":"50","author":"Chiu","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0730","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00609865","article-title":"The pharmacokinetics of cefuroxime after intravenous injection","volume":"12","author":"Gower","year":"1977","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.accpm.2019.07.016_bib0735","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1128\/AAC.00424-08","article-title":"Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men","volume":"52","author":"Cirillo","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0740","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1128\/AAC.46.11.3506-3511.2002","article-title":"Pharmacokinetics of ertapenem in healthy young volunteers","volume":"46","author":"Majumdar","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0745","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF01964413","article-title":"Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males","volume":"10","author":"Nilsson-Ehle","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.accpm.2019.07.016_bib0750","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1093\/jac\/dkt240","article-title":"Population pharmacokinetics and dosing simulations of amoxicillin\/clavulanic acid in critically ill patients","volume":"68","author":"Carlier","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0755","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/jac\/dkq184","article-title":"Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics","volume":"65","author":"Ulldemolins","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0760","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijantimicag.2014.11.005","article-title":"\u03b2-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: a case-control study","volume":"45","author":"Donadello","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.accpm.2019.07.016_bib0765","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/liv.13039","article-title":"Serum \u03b2-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study","volume":"36","author":"Lheureux","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.accpm.2019.07.016_bib0770","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.clinbiochem.2012.03.030","article-title":"Population pharmacokinetics of four \u03b2-lactams in critically ill septic patients comedicated with amikacin","volume":"45","author":"Delattre","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.accpm.2019.07.016_bib0775","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00003246-200102000-00030","article-title":"Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock","volume":"29","author":"Joukhadar","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.accpm.2019.07.016_bib0780","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0785","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkm467","article-title":"Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection","volume":"61","author":"De Jongh","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0790","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/jac\/dku564","article-title":"Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients","volume":"70","author":"Roberts","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0795","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1128\/AAC.00389-15","article-title":"Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies","volume":"59","author":"Sime","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0800","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/cc8941","article-title":"Prospective monitoring of cefepime in intensive care unit adult patients","volume":"14","author":"Chapuis","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.07.016_bib0805","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/AAC.01141-08","article-title":"Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia","volume":"53","author":"Nicasio","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0810","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5414\/CPP46157","article-title":"Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables","volume":"46","author":"Georges","year":"2008","journal-title":"Int J Clin Pharmacol Therap"},{"key":"10.1016\/j.accpm.2019.07.016_bib0815","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkl349","article-title":"Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units","volume":"58","author":"Roos","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0820","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1213\/01.ANE.0000077077.54084.B0","article-title":"Cefepime Versus Cefpirome: the importance of creatinine clearance","author":"Lipman","year":"2003","journal-title":"Anesth Analg"},{"key":"10.1016\/j.accpm.2019.07.016_bib0825","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.43.10.2559","article-title":"Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing","volume":"43","author":"Lipman","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0830","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/jac\/46.2.315","article-title":"Plasma, urine and skin pharmacokinetics of cefepime in burns patients","volume":"46","author":"Sampol","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0835","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00134-007-0573-7","article-title":"Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria","volume":"33","author":"Roos","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.accpm.2019.07.016_bib0840","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s001340000741","article-title":"Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing","volume":"27","author":"Lipman","year":"2001","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.accpm.2019.07.016_bib0845","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1097\/00003246-200207000-00013","article-title":"Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis","volume":"30","author":"Joukhadar","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1016\/j.accpm.2019.07.016_bib0850","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9610(00)00388-3","article-title":"Intermittent and continuous ceftazidime infusion for critically ill trauma patients","volume":"179","author":"Hanes","year":"2000","journal-title":"Am J Surg"},{"key":"10.1016\/j.accpm.2019.07.016_bib0855","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2125.2000.00179.x","article-title":"Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis","volume":"50","author":"Angus","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.accpm.2019.07.016_bib0860","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/49.1.121","article-title":"Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections","volume":"49","author":"Buijk","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0865","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00000542-200009000-00023","article-title":"Ceftriaxone pharmacokinetics during iatrogenic hydroxyethyl starch-induced hypoalbuminemia: a model to explore the effects of decreased protein binding capacity on highly bound drugs","volume":"93","author":"Mimoz","year":"2000","journal-title":"Anesthes"},{"key":"10.1016\/j.accpm.2019.07.016_bib0870","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/jac\/47.4.421","article-title":"The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients","volume":"47","author":"Joynt","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0875","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bcp.12636","article-title":"Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients","volume":"80","author":"Schleibinger","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.accpm.2019.07.016_bib0880","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2125.2011.04005.x","article-title":"Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal","volume":"72","author":"Garot","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.accpm.2019.07.016_bib0885","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/jac\/dku195","article-title":"Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures","volume":"69","author":"Carlier","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0890","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ijantimicag.2012.07.014","article-title":"Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia","volume":"40","author":"Jaruratanasirikul","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.accpm.2019.07.016_bib0895","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1128\/AAC.01543-15","article-title":"Population pharmacokinetics of doripenem in critically Ill patients with sepsis in a Malaysian intensive care unit","volume":"60","author":"Abdul-Aziz","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0900","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1093\/jac\/dku226","article-title":"Unbound fraction of ertapenem in intensive care unit patients","volume":"69","author":"Liebchen","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0905","first-page":"1058","article-title":"Pharmacokinetics of free ertapenem in critically ill septic patients: intermittent versus continuous infusion","volume":"77","author":"Breilh","year":"2011","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.accpm.2019.07.016_bib0910","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ijantimicag.2008.10.005","article-title":"Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis","volume":"33","author":"Brink","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.accpm.2019.07.016_bib0915","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jac\/dkl485","article-title":"Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration","volume":"59","author":"Burkhardt","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0920","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00134-006-0401-5","article-title":"Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia","volume":"32","author":"Boselli","year":"2006","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.accpm.2019.07.016_bib0925","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/0091270005276117","article-title":"Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery","volume":"45","author":"Burkhardt","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.accpm.2019.07.016_bib0930","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1128\/AAC.01318-06","article-title":"Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial","volume":"51","author":"Sakka","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0935","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200544050-00007","article-title":"Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis","volume":"44","author":"Novelli","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.accpm.2019.07.016_bib0940","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1472-8206.2003.00190.x","article-title":"Population pharmacokinetics of imipenem in burn patients","volume":"17","author":"Dailly","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.accpm.2019.07.016_bib0945","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1067\/mcp.2002.122526","article-title":"Tissue distribution of imipenem in critically ill patients","volume":"71","author":"Tegeder","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.accpm.2019.07.016_bib0950","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2011.04.019","article-title":"Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia","volume":"38","author":"Jaruratanasirikul","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.accpm.2019.07.016_bib0955","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0924-8579(01)00474-5","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients","volume":"19","author":"Kitzes-Cohen","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.accpm.2019.07.016_bib0960","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jac\/dkp139","article-title":"Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution","volume":"64","author":"Roberts","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0965","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1186\/s13054-014-0565-2","article-title":"The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study","volume":"18","author":"Shekar","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.07.016_bib0970","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2215\/CJN.10260915","article-title":"Pharmacokinetics and pharmacodynamics of extended infusion versus short infusion piperacillin-tazobactam in critically Ill patients undergoing CRRT","volume":"11","author":"Shotwell","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.accpm.2019.07.016_bib0975","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jac\/dkt304","article-title":"Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic\/pharmacodynamic analysis","volume":"69","author":"As\u00edn-Prieto","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0980","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/cc10257","article-title":"Recommended \u03b2-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy","volume":"15","author":"Seyler","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.07.016_bib0985","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jac\/48.6.881","article-title":"Elimination of the piperacillin\/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure","volume":"48","author":"Valtonen","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0990","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1128\/AAC.46.5.1557-1560.2002","article-title":"Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis","volume":"46","author":"Mueller","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib0995","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2215\/CJN.05690611","article-title":"Pharmacokinetics of ampicillin\/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis","volume":"7","author":"Lorenzen","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.accpm.2019.07.016_bib1000","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000070997","article-title":"How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin","volume":"26","author":"Meyer","year":"2003","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.accpm.2019.07.016_bib1005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijantimicag.2015.05.020","article-title":"Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy","volume":"46","author":"Carlier","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.accpm.2019.07.016_bib1010","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.clinthera.2005.05.004","article-title":"Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients","volume":"27","author":"Isla","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.accpm.2019.07.016_bib1015","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1128\/AAC.45.11.3148-3155.2001","article-title":"Pharmacokinetics of cefepime during continuous renal replacement therapy in critically Ill patients","volume":"45","author":"Malone","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1067\/mcp.2000.105352","article-title":"Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval","volume":"67","author":"Banyai","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.accpm.2019.07.016_bib1025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jac\/49.1.129","article-title":"Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients","volume":"49","author":"Traunm\u00fcller","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1030","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1186\/cc3993","article-title":"Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation","volume":"10","author":"Mariat","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.accpm.2019.07.016_bib1035","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1128\/AAC.01801-15","article-title":"Doripenem treatment during continuous renal replacement therapy","volume":"60","author":"Vossen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1040","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1093\/jac\/dku177","article-title":"Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration","volume":"69","author":"Roberts","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1045","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1248\/yakushi.131.1395","article-title":"Effect of hemopurification rate on doripenem pharmacokinetics in critically ill patients receiving high-flow continuous hemodiafiltration","volume":"131","author":"Ohchi","year":"2011","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.accpm.2019.07.016_bib1050","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/jac\/dku413","article-title":"Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?","volume":"70","author":"Varghese","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1055","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00134-008-1034-7","article-title":"Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy","volume":"34","author":"Langgartner","year":"2008","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.accpm.2019.07.016_bib1060","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.01582-09","article-title":"Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration","volume":"54","author":"Bilgrami","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1065","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000074527","article-title":"Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration","volume":"49","author":"Krueger","year":"2003","journal-title":"Chemotherapy"},{"key":"10.1016\/j.accpm.2019.07.016_bib1070","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/45.5.701","article-title":"Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure","volume":"45","author":"Valtonen","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1075","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1097\/00003246-200010000-00006","article-title":"Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration","volume":"28","author":"Ververs","year":"2000","journal-title":"Critical Care Medicine"},{"key":"10.1016\/j.accpm.2019.07.016_bib1080","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1177\/0091270003260286","article-title":"Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically Ill patients","volume":"43","author":"Robatel","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.accpm.2019.07.016_bib1085","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1177\/0091270005280583","article-title":"Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients","volume":"45","author":"Isla","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.accpm.2019.07.016_bib1090","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1128\/AAC.02090-12","article-title":"Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration","volume":"58","author":"Eyler","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1095","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ndt\/gfn472","article-title":"Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis","volume":"24","author":"Burkhardt","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.accpm.2019.07.016_bib1100","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1128\/AAC.49.6.2421-2428.2005","article-title":"Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients","volume":"49","author":"Fish","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00003088-200847030-00003","article-title":"Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy","volume":"47","author":"Isla","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.accpm.2019.07.016_bib1110","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1128\/AAC.00951-13","article-title":"Protein binding of \u03b2-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1115","doi-asserted-by":"crossref","first-page":"S629","DOI":"10.21037\/jtd.2017.09.154","article-title":"Optimising drug dosing in patients receiving extracorporeal membrane oxygenation","volume":"10","author":"Cheng","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.accpm.2019.07.016_bib1120","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/00003246-199705000-00016","article-title":"Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis","volume":"25","author":"Lugo","year":"1997","journal-title":"Crit Care Med"},{"key":"10.1016\/j.accpm.2019.07.016_bib1125","first-page":"61","article-title":"Influence of mechanical ventilation on the pharmacokinetics of vancomycin administered by continuous infusion in critically ill patients","author":"Medell\u03bdn-Garibay","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1130","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/CCM.0000000000000029","article-title":"Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*","volume":"42","author":"Udy","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.accpm.2019.07.016_bib1135","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijantimicag.2014.12.017","article-title":"Augmented renal clearance, low \u03b2-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study","volume":"45","author":"Huttner","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.accpm.2019.07.016_bib1140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijantimicag.2016.12.022","article-title":"Association between augmented renal clearance and clinical outcomes in patients receiving \u03b2-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial","volume":"49","author":"Udy","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.accpm.2019.07.016_bib1145","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.1128\/AAC.01291-12","article-title":"Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics\/pharmacodynamics-based approach","volume":"56","author":"Pea","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.accpm.2019.07.016_bib1155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2110-5820-2-1","volume":"2","author":"Vinsonneau","year":"2012","journal-title":"Ann Intens Care"},{"key":"10.1016\/j.accpm.2019.07.016_bib1160","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.accpm.2019.07.016_bib1165","first-page":"1","article-title":"Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.accpm.2019.07.016_bib1170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00654-17","article-title":"Neurotoxic Concentration of Piperacillin during Continuous Infusion in Critically Ill Patients","volume":"61","author":"Quinton","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.accpm.2019.07.016_bib1175","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ijantimicag.2010.01.018","article-title":"Daily serum piperacillin monitoring is advisable in critically ill patients","volume":"35","author":"Blondiaux","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.accpm.2019.07.016_bib1180","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.accpm.2019.07.016_bib1185","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.burns.2015.01.001","article-title":"Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients","volume":"41","author":"Fournier","year":"2015","journal-title":"Burns"},{"key":"10.1016\/j.accpm.2019.07.016_bib1190","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijantimicag.2017.01.009","article-title":"Impact of \u03b2-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy","volume":"49","author":"Economou","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.accpm.2019.07.016_bib1195","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cmi.2016.04.019","article-title":"The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for \u03b2-lactam administration and therapeutic drug monitoring among critically ill patients in France","volume":"22","author":"Charmillon","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.accpm.2019.07.016_bib1200","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijantimicag.2015.06.016","article-title":"Assays for therapeutic drug monitoring of \u03b2-lactam antibiotics: A structured review","volume":"46","author":"Carlier","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.accpm.2019.07.016_bib1205","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.clinbiochem.2009.12.007","article-title":"Empirical models for dosage optimization of four \u03b2-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin","volume":"43","author":"Delattre","year":"2010","journal-title":"Clin Biochem"}],"container-title":["Anaesthesia Critical Care & Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352556819301389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352556819301389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:45:09Z","timestamp":1762479909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352556819301389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2352556819301389"],"URL":"https:\/\/doi.org\/10.1016\/j.accpm.2019.07.016","relation":{},"ISSN":["2352-5568"],"issn-type":[{"value":"2352-5568","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic variability of beta-lactams in critically ill patients: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Anaesthesia Critical Care & Pain Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.accpm.2019.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise d'anesth\u00e9sie et de r\u00e9animation (Sfar). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}